These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 22332457

  • 1. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
    Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.
    Manag Care; 2012 Jan; 21(1):49-58. PubMed ID: 22332457
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF, Plosker GL.
    CNS Drugs; 2004 Apr; 18(7):469-73. PubMed ID: 15139801
    [Abstract] [Full Text] [Related]

  • 9. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.
    Pharmacoeconomics; 2008 Apr; 26(11):969-81. PubMed ID: 18850765
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance.
    Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.
    Am J Manag Care; 2011 Aug 01; 17(8):e314-23. PubMed ID: 21851139
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K, Hemels ME, Hudry J, Annemans L.
    Clin Ther; 2005 Jan 01; 27(1):111-24. PubMed ID: 15763612
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
    McLaughlin TP, Eaddy MT, Grudzinski AN.
    Clin Ther; 2004 Jan 01; 26(1):115-24. PubMed ID: 14996524
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar 01; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 20. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF, Plosker GL.
    Pharmacoeconomics; 2003 Mar 01; 21(16):1185-209. PubMed ID: 14594439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.